Three months of romosozumab did not improve hip bone strength, but 12 months did, supporting completion of the full regimen in patients with osteoporosis.
Koji Ishikawa, MD, PhD
Advertisement
Koji Ishikawa, MD, PhD, is a senior research associate in the Alman Lab at Duke Orthopaedic Surgery.
Articles by Koji Ishikawa, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement